552,506 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Redmile Group LLC

Redmile Group LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) in the 1st quarter, HoldingsChannel reports. The firm bought 552,506 shares of the company’s stock, valued at approximately $36,576,000. Keros Therapeutics accounts for about 1.3% of Redmile Group LLC’s holdings, making the stock its 29th largest position.

Other large investors have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. boosted its stake in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 356.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock valued at $138,000 after purchasing an additional 2,702 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Keros Therapeutics by 117.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock valued at $345,000 after purchasing an additional 2,822 shares during the period. Arizona State Retirement System purchased a new position in Keros Therapeutics in the 4th quarter worth about $231,000. Finally, Perpetual Ltd purchased a new position in Keros Therapeutics in the 1st quarter worth about $443,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Price Performance

KROS traded down $0.29 on Monday, reaching $52.03. 518,449 shares of the company traded hands, compared to its average volume of 387,773. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -10.10 and a beta of 1.23. The stock’s 50 day moving average price is $47.34 and its 200-day moving average price is $55.45. Keros Therapeutics, Inc. has a 52-week low of $27.02 and a 52-week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.12. The company had revenue of $0.08 million for the quarter. During the same quarter in the prior year, the company posted ($1.26) EPS. The firm’s quarterly revenue was down 97.3% compared to the same quarter last year. As a group, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

KROS has been the subject of several recent analyst reports. Oppenheimer initiated coverage on shares of Keros Therapeutics in a report on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Finally, Truist Financial reiterated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $92.17.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.